<DOC>
	<DOCNO>NCT02245438</DOCNO>
	<brief_summary>Study characterize effect two dose combination Tipranavir ( TPV ) /Ritonavir ( RTV ) ( TPV 750 mg/RTV 200 mg TPV 500 mg/RTV 100 mg ) , administer twice-daily , pharmacokinetics Norethindrone-Ethinyl Estradiol ( NET/EE ) 1 mg/ 0.035 mg administer single dose .</brief_summary>
	<brief_title>Effect Tipranavir Ritonavir Pharmacokinetic Characteristics Norethindrone-Ethinyl Estradiol Healthy Female Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<criteria>1 . Female subject 18 50 year age inclusive 2 . A Body Mass Index ( BMI ) 18 29 kg/m2 3 . Signed informed consent prior trial participation 4 . Ability swallow numerous large capsule without difficulty 5 . Acceptable laboratory value indicate adequate baseline organ function require time screen . Laboratory value consider acceptable severity less equal Grade 1 , base AIDS Clinical Trials Group Grading Scale . All abnormal laboratory value great Grade 1 subject approval trial clinical monitor . 6 . Acceptable medical history , physical examination ECG , chest Xray ( conduct within last 12 month ) require prior enter treatment phase study 7 . Willingness abstain alcohol 48 hour prior Study Day 0 abstain alcohol duration study . In addition , red wine must ingest within 5 day prior Day 0 ( Visit 2 ) 8 . Willingness abstain ingest grapefruit , grapefruit juice , product contain grapefruit juice , within 10 day Day 0 , Visit 2 duration study 9 . Willingness abstain ingest Seville orange , garlic supplement , St. John 's Wort , Milk Thistle , methylxanthinecontaining drink food ( coffee , tea , cola , energy drink , chocolate , etc ) within 5 day Day 0 , Visit 2 duration study 10 . Willingness abstain counter herbal medication duration study 11 . Reasonable probability completion study 1 . Female subject reproductive potential : Have positive serum betahuman chorionic gonadotropin Visit 1 , Day 0 Day 1 Have use barrier contraceptive method least 3 month prior Visit 3 ( Day 1 ) Are willing use reliable method doublebarrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , trial 30 day completion/termination Are breastfeed 2 . Participation another trial investigational medicine within 30 day prior Day 0 ( Visit 2 ) 3 . Use medication list protocol within 30 day prior Day 0 ( Visit 2 ) 4 . Use pharmacological contraceptive ( include oral , patch injectable contraceptive ) 1 month prior study initiation duration study 5 . Administration antibiotic within 10 day prior Day 0 ( Visit 2 ) trial 6 . History central nervous system ( CNS ) , gastrointestinal , hepatic , renal disorder within past sixty ( 60 ) day . Subjects exclude disorder great sixty day , opinion investigator , subject qualify healthy volunteer 7 . History thrombotic disease 8 . History migraine headache 9 . Have serological evidence hepatitis B C virus 10 . Have serological evidence exposure HIV 11 . Recent history alcohol substance abuse ( within 6 month study period ) 12 . Cigarette smoking ( great 10 cigarette per day ) 13 . Blood plasma donation within 30 day prior Day 0 ( Visit 2 ) trial . 14 . Subjects seat systolic blood pressure either &lt; 100 mm Hg &gt; 150 mm Hg ; rest heart rate either &lt; 50 beats/min &gt; 90 beats/min . For subject rest heart rate 50 , due high fitness level , investigator may discuss exclusion medical monitor casebycase basis 15 . Subjects history illness allergy , opinion investigator , might confound result study pose additional risk administer Tipranavir , Ritonavir NET/EE subject 16 . Subjects acute illness within 2 week prior Day 0 ( Visit 2 ) 17 . Subjects currently take overthecounter drug within 7 day prior Day 0 , ( Visit 2 ) currently take prescription drug , opinion investigator consultation clinical monitor , might interfere either absorption , distribution metabolism test substances 18 . Known hypersensitivity TPV , RTV , NET/EE 19 . Inability comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>